Bis-arylidene oxindoles as anti-breast-cancer agents acting via the estrogen receptor

Area of Science:

• Medicinal Chemistry
• Oncology
• Endocrinology

Background:

• Estrogen receptor (ER)-positive breast cancer relies on estrogen for growth.
• Selective ER modulators (SERMs) are crucial for treating ER+ breast cancer.
• Development of novel, potent, and selective anticancer agents is ongoing.

Purpose of the Study:

• To synthesize and evaluate a new family of bis-arylidene oxindole derivatives.
• To assess the selective ER-mediated anticancer activity of these compounds.
• To compare their efficacy against existing breast cancer therapies.

Main Methods:

• Synthesis of novel bis-arylidene oxindole derivatives.
• In vitro evaluation of cell growth inhibition in ER-positive and ER-negative breast cancer cells.
• Comparison of IC50 values and toxicity profiles with tamoxifen and 4-hydroxytamoxifen.
• Assessment of ER transactivation inhibition and ER depletion effects.

Main Results:

• Compounds exhibited highly selective ER-mediated anticancer activity at low-nanomolar concentrations in ER+ cells.
• IC50 values were significantly lower in ER+ breast cancer cells compared to ER- breast cancer and non-cancer cells.
• The novel oxindoles demonstrated superior toxicity compared to tamoxifen and 4-hydroxytamoxifen in ER+ MCF-7 cells.
• Inhibition of ER transactivation and selective ER down-regulation properties were observed.

Conclusions:

• Bis-arylidene oxindole derivatives represent a promising new class of anticancer agents.
• These compounds show high selectivity and potency for estrogen-responsive breast cancer.
• Further development could lead to novel therapeutic strategies for ER+ breast cancer.